PT - JOURNAL ARTICLE AU - Gunes, Aysim AU - Bilodeau, Laurent AU - Huet, Catherine AU - Belblidia, Assia AU - Baldwin, Cindy AU - Giard, Jeanne-Marie AU - Biertho, Laurent AU - Lafortune, Annie AU - Couture, Christian Yves AU - Nguyen, Bich N AU - Galun, Eithan AU - Bémeur, Chantal AU - Bilodeau, Marc AU - Laplante, Mathieu AU - Tang, An AU - Faraj, May AU - Estall, Jennifer L. TI - Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity AID - 10.1101/2022.01.10.22268968 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.10.22268968 4099 - http://medrxiv.org/content/early/2022/01/11/2022.01.10.22268968.short 4100 - http://medrxiv.org/content/early/2022/01/11/2022.01.10.22268968.full AB - Background Nonalcoholic steatohepatitis (NASH) is a metabolic disease associated with liver failure and cancer. Accurate monitoring of advancing NASH is challenging. There are few reliable, non-invasive biomarkers of early NASH. Since liver inflammation is a main driver of fibrosis, we investigated relationships between circulating components of the interleukin-6 signaling pathway (IL-6, sIL-6R and sgp130) and liver pathology in subjects with NAFLD and NASH.Methods Predictive performance of plasma IL-6, sIL-6R and sgp130 were investigated in two independent cohorts: 1) patients with biopsy-confirmed NASH (n=49), where magnetic resonance spectroscopy (MRS), imaging (MRI) and elastography (MRE) assessed liver fat, volume and stiffness; and 2) patients with morbid obesity (n=245) undergoing bariatric surgery where Bedossa algorithm and steatosis, activity, and fibrosis scores assessed NASH severity. Correlations were evaluated between circulating IL-6, sIL-6R and sgp130 and anthropomorphic characteristics, plasma markers of metabolic disease or liver pathology, adjusting for covariates of liver disease such as age, sex, BMI and diabetes.Results In patients with NASH, plasma IL-6 and sgp130 strongly correlated with liver stiffness, which for sgp130, was independent of age, sex, BMI, and chronic disease (diabetes, hyperlipidemia, hypertension or history of HCC). Plasma sgp130 was the strongest predictor of liver stiffness compared to commonly used biomarkers and predictive algorithms. Plasma sIL-6R correlated with liver volume independent of age, sex, and BMI. In stepwise forward regression analysis, plasma sgp130 followed by NAFLD fibrosis score and plasma globulin, predicted up to 74% of liver stiffness with/without adjustment for sex. In morbidly obese subjects, circulating IL-6 correlated with hepatocellular ballooning and sgp130 correlated with advanced liver fibrosis.Conclusions Circulating sgp130 could represent a robust biomarker of active NASH and may be used alone or in combination with other biomarkers as a non-invasive measure of liver disease severity.Competing Interest StatementLaurent Biertho receives funding from Johnson & Johnson Medical Companies, Medtronic, Bodynov and GI Windows for studies on bariatric surgery. An Tang received a speaking honorarium from Eli Lilly.Funding StatementThis work was supported by unrestricted operating grants from the Merck, Sharpe and Dohme Corporation/University of Montreal and the International Development Research Centre (108591-001), and program support from the Quebec Ministry of Economy and Innovation. JLE and AT are supported by Chercheurs-boursiers: Senior awards from the Fonds de recherche du Quebec Sante. The ULaval Biobank is supported by the IUCPQ Foundation and Research Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committees of the: Centre hospitalier de Universite de Montreal; Institut de recherches clinique de Montreal; and Institut universitaire de cardiologie et de pneumologie de Quebec, Universite Laval gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors